Table 1.
Sweden | China | |||
---|---|---|---|---|
Controls | MPN | Controls | MPN | |
Number | 756 | 126 | 101 | 101 |
Age (years) | ||||
Mean ± SD | 64 ± 5 | 64 ± 14 | 58 ± 15 | 58 ± 15 |
Median (range) | 64 (54–74) | 65 (25–106) | 60 (17–82) | 60 (17–82) |
Sex [%females] | 53 | 53 | 50 | 50 |
MPN subtype, n (%) | ||||
PV | 41 (32.5) | 16 (15.8) | ||
ET | 40 (31.7) | 38 (37.6) | ||
PMF | 28 (22.3) | 15 (14.9) | ||
MPN-NOS | 17 (13.5) | 32 (31.7) | ||
JAK2-status, n (%) | ||||
JAK2 V617F− | 60 (47.6) | 38 (37.6) | ||
JAK2 V617F+ | 66 (52.4) | 56 (55.4) | ||
Unknown | 0 | 7 (7.0) | ||
CALR mutation | 45 | Unknown |
MPN myeloproliferative neoplasm, PV polycythemia vera, ET essential thrombocythemia, PMF primary myelofibrosis